PDL BioPharma traded down 0.40% on Friday, hitting $7.48. PDL BioPharma has a 52-week low of $5.76 and a 52-week high of $8.43. The company has a market cap of $1.047 billion and a price-to-earnings ratio of 5.55.
PDL BioPharma last posted its quarterly earnings results on Monday, November 5th. The company reported $0.32 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.33 by $0.01. The company had revenue of $85.20 million for the quarter, compared to the consensus estimate of $85.03 million. During the same quarter in 2011, the company posted $0.28 earnings per share. The company?s revenue for the quarter was up 2.2% on a year-over-year basis. On average, analysts predict that PDL BioPharma will post $1.42 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse initiated coverage on shares of PDL BioPharma in a research note to investors on Thursday, December 6th. They set a ?neutral? rating on the stock.
PDL BioPharma, Inc. (PDL) is engaged in the management of its antibody humanization patents and royalty assets, which consist of the Company?s Queen et al. To view Zacks? full report, visit www.zacks.com
Stay on top of analysts’ coverage with American Banking & Market News’ that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day..